Edition:
United States

Actelion Ltd (ALIOF.PK)

ALIOF.PK on OTC Markets Group

279.00USD
27 Mar 2017
Change (% chg)

$3.80 (+1.38%)
Prev Close
$275.20
Open
$276.52
Day's High
$279.00
Day's Low
$276.52
Volume
528
Avg. Vol
3,078
52-wk High
$279.00
52-wk Low
$138.01

Latest Key Developments (Source: Significant Developments)

Actelion says drug discovery business to be called Idorsia
Wednesday, 15 Mar 2017 02:40am EDT 

Actelion Ltd :Says drug discovery and early clinical pipeline business will be separated into a newly-created entity called idorsia ltd -- agm invitation.  Full Article

Actelion says granted marketing authorization by European Commission for Ledaga
Tuesday, 7 Mar 2017 01:00am EST 

Actelion Ltd :Actelion is granted marketing authorization by the European Commission for Ledaga (chlormethine gel) for the treatment of MF-CTCL.  Full Article

Swiss Takeover Commission OKs J&J offer for Actelion
Thursday, 16 Feb 2017 03:01am EST 

Actelion Ltd :Swiss Takeover Commission says J&J offer for Actelion meets legal requirements.  Full Article

BRIEF-J&J says upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee
Wednesday, 1 Feb 2017 04:05pm EST 

Corrects source to Johnson & Johnson from Actelion Ltd.Johnson & Johnson :J&J - upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee - sec filing.  Full Article

J&J has two-year agreement on stake in R&D company
Thursday, 26 Jan 2017 09:04am EST 

Johnson & Johnson : J&J says on investor call it has two year agreement not to sell on the open market any equity stake in actelion research and development unit . J&J says won't speculate on how long it will hold stake in research and development company (Reporting By Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

Actelion CEO hopes new R&D business to collaborate with J&J on products
Thursday, 26 Jan 2017 08:04am EST 

Actelion : Ceo says new research company to concentrate on development, focus on research for 1-2 years . Ceo says new company to have about 600 employees . Ceo says not sure of success of new company, but "very confident" . Ceo says new company will start with $1 billion in cash, 14 investigational products . Ceo says hopes to collaborate with j&j on products from new research and development company that he will head . Ceo says says will get potential royalties from ms drug, antibiotic from j&j . Ceo says did not speak with shareholder rudolf maag about transaction, "he has read about the deal this morning. I think he's going to like it." . Cfo says says source of cash in new company will be j&j equity stake, cash spun off from actelion demerger into new company . Ceo says nearly no overlap of companies to cause antitrust concerns .CEO says "With this structure it was not difficult. It's always emotional but it's not difficult. Because frankly it's a good solution for everybody.".  Full Article

Jupiter says J&J purchase of Actelion "very good outcome"
Thursday, 26 Jan 2017 06:00am EST 

: Jupiter Fund Manager Mike Buhl-nielsen: Johnson & Johnson purchase of actelion is "very good outcome", says can see "clear synergies for j&j" . Buhl-Nielsen holds Actelion shares Further company coverage: [JNJ.N] [ATLN.S] ((carolyn.cohn@thomsonreuters.com;)).  Full Article

Sanofi in advanced talks to buy Actelion- Bloomberg, citing sources
Thursday, 15 Dec 2016 08:43pm EST 

:Sanofi said to be in advanced talks to buy drugmaker Actelion, companies discussing price of about $275 per actelion share- bloomberg, citing sources.  Full Article

Actelion says in discussions with another party regarding possible strategic transaction
Tuesday, 13 Dec 2016 08:11pm EST 

Actelion Ltd : Actelion - Actelion is engaged in discussions with another party regarding a possible strategic transaction . Actelion update on strategic transaction discussions . Actelion - Confirms that J&J has withdrawn from the discussions .Actelion - There can be no certainty at this point that any transaction will result.  Full Article

Sanofi to explore counterbid for Actelion amid J&J talks - Bloomberg, citing sources
Monday, 5 Dec 2016 04:25pm EST 

:Sanofi to explore counterbid for Actelion amid J&J talks - Bloomberg, citing sources.  Full Article

More From Around the Web

UPDATE 3-Icahn buys Bristol-Myers shares, adding to activist pressure

Feb 21 Billionaire investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co and sees the drugmaker as a possible takeover target, according to a report published on Tuesday that sent the company's shares from a loss to more than 2 percent higher.